IL202647A - Use of a voluntary L-type calcium channel inhibitor to prepare a cure for cerebrovascular disease and pharmaceutical preparations for this treatment - Google Patents

Use of a voluntary L-type calcium channel inhibitor to prepare a cure for cerebrovascular disease and pharmaceutical preparations for this treatment

Info

Publication number
IL202647A
IL202647A IL202647A IL20264709A IL202647A IL 202647 A IL202647 A IL 202647A IL 202647 A IL202647 A IL 202647A IL 20264709 A IL20264709 A IL 20264709A IL 202647 A IL202647 A IL 202647A
Authority
IL
Israel
Prior art keywords
treatment
medicament
manufacture
pharmaceutical compositions
calcium channel
Prior art date
Application number
IL202647A
Other languages
English (en)
Hebrew (he)
Other versions
IL202647A0 (en
Original Assignee
Loch R Macdonald
Brian Leuthner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loch R Macdonald, Brian Leuthner filed Critical Loch R Macdonald
Publication of IL202647A0 publication Critical patent/IL202647A0/en
Publication of IL202647A publication Critical patent/IL202647A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL202647A 2007-06-11 2009-12-10 Use of a voluntary L-type calcium channel inhibitor to prepare a cure for cerebrovascular disease and pharmaceutical preparations for this treatment IL202647A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94312407P 2007-06-11 2007-06-11
US97690207P 2007-10-29 2007-10-29
PCT/US2008/066576 WO2008154585A1 (en) 2007-06-11 2008-06-11 A drug delivery system for the prevention of cerebral vasospasm

Publications (2)

Publication Number Publication Date
IL202647A0 IL202647A0 (en) 2010-06-30
IL202647A true IL202647A (en) 2015-02-26

Family

ID=40096090

Family Applications (1)

Application Number Title Priority Date Filing Date
IL202647A IL202647A (en) 2007-06-11 2009-12-10 Use of a voluntary L-type calcium channel inhibitor to prepare a cure for cerebrovascular disease and pharmaceutical preparations for this treatment

Country Status (10)

Country Link
US (2) US8303974B2 (enExample)
EP (1) EP2164497B1 (enExample)
JP (1) JP5576790B2 (enExample)
KR (3) KR101554258B1 (enExample)
CN (3) CN105055300A (enExample)
AU (1) AU2008261668C1 (enExample)
CA (1) CA2690600C (enExample)
IL (1) IL202647A (enExample)
NZ (2) NZ581836A (enExample)
WO (1) WO2008154585A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8303974B2 (en) * 2007-06-11 2012-11-06 Edge Therapeutics, Inc. Drug delivery system for the prevention of cerebral vasospasm
US10092524B2 (en) * 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
US9364432B2 (en) * 2007-06-11 2016-06-14 Edge Therapeutics, Inc. Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
EP2308478A1 (en) 2009-10-06 2011-04-13 Abbott GmbH & Co. KG Delivery system for sustained release of a calcium-channel blocking agent
WO2011103591A1 (en) * 2010-02-22 2011-08-25 Edge Therapeutics Inc. Methods and compositions to treat hemorrhagic conditions of the brain
US8658676B2 (en) * 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
PL2627173T5 (pl) 2010-10-12 2019-11-29 Chiesi Farm Spa Formulacje emulsyjne klewidypiny zawierające środki przeciw mikrobom
EP2672983B1 (en) * 2011-02-11 2017-04-19 Edge Therapeutics, Inc. Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage
CN102416013A (zh) * 2011-12-30 2012-04-18 湖南九典制药有限公司 西尼地平的新用途
US9399019B2 (en) * 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof
WO2014165023A1 (en) 2013-03-12 2014-10-09 Carnegie Mellon University Coated vaso-occclusive device for treatment of aneurysms
CN103211812A (zh) * 2013-04-02 2013-07-24 苏州大学附属第一医院 Skf96365在治疗蛛网膜下腔出血后发生的脑血管痉挛的应用
US10403395B2 (en) * 2013-10-14 2019-09-03 SecondOpinionExpert, Inc. Method and apparatus for generating objective medical second opinion
JP2018506530A (ja) * 2015-01-30 2018-03-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脊柱軟膜下遺伝子送達システム
GB2556500A (en) * 2015-05-29 2018-05-30 Edge Therapeutics Inc Compositions and methods for reducing visual loss
CA2994544C (en) 2015-08-03 2021-03-30 Enb Therapeutics, Llc Compositions and methods for treating cancers associated with etbr activation
BR112020000506A2 (pt) * 2017-07-11 2020-07-14 Sustained Nano Systems Llc formulações farmacêuticas hipercomprimidas
EA202091630A1 (ru) 2018-01-12 2020-12-04 Инб Терапьютикс, Инк. Дейтерированные соединения, композиции и способы для лечения раков, связанных с активацией etbr
US20200163947A1 (en) * 2018-11-02 2020-05-28 Nortic Holdings Inc. Methods of treatment using nimodipine parenteral formulations
US11103142B2 (en) * 2019-04-02 2021-08-31 Tencent America LLC System and method for predicting vertebral artery dissection
US20200315547A1 (en) * 2019-04-02 2020-10-08 Tencent America LLC Vertebral artery dissection risk evaluation method, computer device, and storage medium
JP7716076B2 (ja) * 2021-02-04 2025-07-31 学校法人産業医科大学 血管内穿孔によるくも膜下出血モデルの血腫を可視化する方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
CA2180526A1 (en) 1994-01-05 1995-07-13 Joseph C. Hogan, Jr. Method of identifying chemical compounds having selected properties for a particular application
US5712171A (en) 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
JP2909418B2 (ja) * 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
WO1997033552A1 (en) 1996-03-12 1997-09-18 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
US6123956A (en) 1997-07-10 2000-09-26 Keith Baker Methods for universally distributing therapeutic agents to the brain
US6284283B1 (en) * 1999-10-21 2001-09-04 Alkermes Controlled Therapeutics, Inc. Method of producing sub-micron particles of biologically active agents and uses thereof
JP2002003406A (ja) * 2000-06-21 2002-01-09 Sankyo Co Ltd 脳血管攣縮予防製剤
US20030032676A1 (en) * 2001-08-09 2003-02-13 Kimelberg Harold K. Drugs for treatment of cerebral injury and methods of use thereof
US20040224030A1 (en) * 2003-05-06 2004-11-11 Shastri Venkatram R. Microsphere delivery systems
CA2533592C (en) * 2003-07-23 2015-11-10 Pr Pharmaceuticals, Inc. Controlled release compositions
CN1480128A (zh) * 2003-08-06 2004-03-10 北京扬新科技有限公司 一种透明、隐形的外用药物制剂
CN1856296A (zh) * 2003-09-30 2006-11-01 阿库斯菲尔公司 可注射的、口服、或局部用缓释药物制剂
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US7829527B2 (en) * 2005-02-02 2010-11-09 University Of Vermont And State Agricultural College Emergence of a R-type Ca2+ channel (Cav 2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage
US20060217340A1 (en) * 2005-03-23 2006-09-28 University Of Vermont And State Agricultural College Methods and products for treating hypertension by modulation of TRPC3 channel activity
US8303974B2 (en) * 2007-06-11 2012-11-06 Edge Therapeutics, Inc. Drug delivery system for the prevention of cerebral vasospasm

Also Published As

Publication number Publication date
KR101554250B1 (ko) 2015-09-18
AU2008261668A1 (en) 2008-12-18
KR101554258B1 (ko) 2015-09-18
KR20150015514A (ko) 2015-02-10
EP2164497B1 (en) 2018-08-15
JP5576790B2 (ja) 2014-08-20
AU2008261668B2 (en) 2013-08-29
CA2690600A1 (en) 2008-12-18
KR20150061031A (ko) 2015-06-03
EP2164497A4 (en) 2013-05-29
US8303974B2 (en) 2012-11-06
CN105963242A (zh) 2016-09-28
CA2690600C (en) 2016-10-11
AU2008261668C1 (en) 2014-01-16
IL202647A0 (en) 2010-06-30
NZ599430A (en) 2014-03-28
CN101873858A (zh) 2010-10-27
KR101607244B1 (ko) 2016-03-30
CN105055300A (zh) 2015-11-18
JP2010529205A (ja) 2010-08-26
US20130022660A1 (en) 2013-01-24
EP2164497A1 (en) 2010-03-24
US20080305147A1 (en) 2008-12-11
NZ581836A (en) 2012-07-27
WO2008154585A1 (en) 2008-12-18
KR20100055385A (ko) 2010-05-26
CN101873858B (zh) 2016-05-25

Similar Documents

Publication Publication Date Title
IL202647A (en) Use of a voluntary L-type calcium channel inhibitor to prepare a cure for cerebrovascular disease and pharmaceutical preparations for this treatment
IL197169A0 (en) Use of fgf-18 in the manufacture of a medicament for treatment of cartilage disorders
GB2461412B (en) Methods and compositions for reduction of side effects of therapeutic treatments
EP2099449A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES THAT COME WITH IMPOTENCE
PL2322221T3 (pl) Kompozycja farmaceutyczna do leczenia i zapobiegania raka
PL2601962T3 (pl) Schemat dawkowania LAG-3 do stosowania w leczeniu raka
HUE042083T2 (hu) Készítmények fájdalom és/vagy gyulladás kezelésére
IL218169A (en) Quinazoline compounds and their pharmaceutical compositions containing them for use in therapy
IL207546A0 (en) Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
IL206080A0 (en) Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
EP2219448A4 (en) THERAPEUTIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASES AND SUFFERINGS
EP2079526A4 (en) COMPOSITIONS AND ITS USES IN THE TREATMENT OF WOUNDS
IL198723A0 (en) Methods and compositions for therapeutic treatment
ZA201200944B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
IL218277B (en) Tetracycline compounds, pharmaceutical preparations containing them and their use for the preparation of medicines for the treatment and prevention of infection
PL2121025T3 (pl) Sposoby i kompozycje dla dostarczania czynnika terapeutycznego
EP2135866A4 (en) NEW DIHYDROPYRMIDINE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT AND PREVENTION OF VIRUSES
IL202307A (en) Multikinase inhibitors for use in the preparation of pharmaceuticals for the treatment of various cancers
EP2387407A4 (en) MEDICAMENT FOR THE TREATMENT OF PAIN AND INFLAMMATION
EP2056857A4 (en) PHARMACEUTICAL COMPOSITIONS WITH CCL2 AND THEIR USE IN THE TREATMENT OF INFLAMMATION
EP2145623A4 (en) PHARMACEUTICAL AND COSMETIC COMPOSITIONS FOR ACCELERATING THE PROCESS OF WOUND HEALING AND OTHER SURFACE INJURIES
PL2305300T3 (pl) Kompozycja farmaceutyczna do leczenia i zapobiegania nowotworowi
IL194066A0 (en) Therapeutic composition for treatment of tinnitus
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
ZA200900556B (en) Use of flumazenil in the manufacture of a medicament for the treatment of depressive disorders

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed